Yunnan Baiyao

Verify with FDA CVM →

27 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
27
Total Reports
9
Deaths Reported
3330.0%
Death Rate

Active Ingredients

Yunnan Baiyao

Administration Routes

OralUnknown

Species Affected

Dog 25
Cat 2

Most Affected Breeds

Retriever - Golden 4
Rottweiler 2
Crossbred Canine/dog 2
Chow Chow 2
Boxer (German Boxer) 2
Shar Pei 1
Bulldog 1
Spaniel (unspecified) 1
Siberian Husky 1
Shepherd Dog - German 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 7
Anaemia NOS 6
Death by euthanasia 6
Decreased appetite 5
Thrombocytopenia 5
Low platelet count 5
Neutrophilia 5
Monocytosis 5
Pale mucous membrane 4
Oral bleeding 4
Other abnormal test result NOS 4
Leucocytosis NOS 4

Outcome Breakdown

Ongoing
15 (55.6%)
Euthanized
6 (22.2%)
Outcome Unknown
3 (11.1%)
Died
3 (11.1%)

Data Summary

Metric Value
Total adverse event reports 27
Reports involving death 9
Case-fatality rate (reported events) 3330.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Yunnan Baiyao Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 27 adverse event reports referencing Yunnan Baiyao, including 9 reports in which the animal died — a 3330.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Yunnan Baiyao. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Yunnan Baiyao reports are Dog (25 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Golden (4), Rottweiler (2), Crossbred Canine/dog (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Yunnan Baiyao are Lethargy (see also Central nervous system depression in Neurological) (7), Anaemia NOS (6), Death by euthanasia (6), Decreased appetite (5). Of the 27 reports with a coded outcome, Ongoing is the leading category at 55.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Yunnan Baiyao.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial